Public Summary

Summary for ARTG Entry:	282868	Ellura
ARTG entry for	Medicine Listed	
Sponsor	SFI Australasia	
Postal Address	PO Box 1027, CROWS NEST, NSW, 1585 Australia	
ARTG Start Date	24/11/2016	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . Ellura

Product Type Single Medicine Product **Effective Date** 14/01/2020

Permitted Indications

Maintain/support bladder health in healthy females

Maintain/support bladder health in children

Maintain/support bladder health

Helps reduce occurrence of medically diagnosed cystitis in children

Helps reduce occurrence of medically diagnosed cystitis

Helps reduce occurrence of medically diagnosed cystitis in healthy females

Maintain/support urinary tract health in children

Maintain/support urinary tract health

Maintain/support urinary tract health in healthy females

Aid/assist flushing of the urinary tract

Indication Requirements

Product presentation must only refer to medically diagnosed cystitis.

Label statement: If pain or irritation persists for more than 48 hours, consult your doctor. The presence of blood in the urine warrants immediate medical attention (or words to that effect).

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

If symptoms persist consult your healthcare practitioner (or words to that effect).

Additional Product information

Pack Size/Poison information

Pack Size	Poison Schedule

Components

1 . Formulation 1

Dosage Form	Capsule, hard
Route of Administration	Oral
Visual Identification	

Active Ingredients

Vaccinium macrocarpon fruit Juice powder standardised	**206 mg**
Equivalent: Vaccinium macrocarpon (Fresh)	50 g

Other Ingredients (Excipients)

colloidal anhydrous silica
hypromellose
magnesium stearate
mannitol